{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:42Z","timestamp":1787013942057,"version":"build-2736575974"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:00:00Z","timestamp":1735084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","award":["P21589"],"award-info":[{"award-number":["P21589"]}],"id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>This pilot study evaluated CPX\u2010351 in adults with newly diagnosed, favourable\u2010intermediate risk, FLT3\u2010ITD\u2010negative AML. Twenty patients received CPX\u2010351 for induction, with six also receiving gemtuzumab ozogamicin (GO). The complete response rate was 95%, with 42% achieving flow\u2010based minimal residual disease (MRD) negativity post\u2010induction. The 18\u2010month leukaemia\u2010free and overall survival estimates were 80% and 95% respectively. Adding GO appeared safe without prolonged cytopenias. Subclinical cardiotoxicity was observed in 25% of patients. The study demonstrated CPX\u2010351's feasibility, with response and MRD\u2010negativity rates comparable to standard \u20187\u2009+\u20093\u2019 induction.<\/jats:p>","DOI":"10.1111\/bjh.19967","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T18:34:31Z","timestamp":1735151671000},"page":"551-555","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CPX\u2010351 +\/\u2212 gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable\u2010intermediate risk, FLT3\u2010ITD negative, AML: A pilot study"],"prefix":"10.1111","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-4807","authenticated-orcid":false,"given":"Chezi","family":"Ganzel","sequence":"first","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Department, the Eisenberg R&amp;D Authority, Shaare Zedek Medical Center, and Faculty of Medicine Hebrew University  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avraham","family":"Frisch","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Rambam Health Care Campus  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofir","family":"Wolach","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center \u2013 Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakir","family":"Moshe","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Unit Tel Aviv Sourasky Medical Center  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baher","family":"Krayem","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Rambam Health Care Campus  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neta","family":"Dor","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Department, the Eisenberg R&amp;D Authority, Shaare Zedek Medical Center, and Faculty of Medicine Hebrew University  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etti","family":"Broide","sequence":"additional","affiliation":[{"name":"Flow Cytometry Laboratory Shaare Zedek Medical Center  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Benayoun","sequence":"additional","affiliation":[{"name":"Flow Cytometry Laboratory Shaare Zedek Medical Center  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Department, the Eisenberg R&amp;D Authority, Shaare Zedek Medical Center, and Faculty of Medicine Hebrew University  Jerusalem Israel"},{"name":"Department of Hematology and Bone Marrow Transplantation Rambam Health Care Campus  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5521-1337","authenticated-orcid":false,"given":"Yishai","family":"Ofran","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Department, the Eisenberg R&amp;D Authority, Shaare Zedek Medical Center, and Faculty of Medicine Hebrew University  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,25]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00134-4"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013626"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904544"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-540971"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.1753"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404313"},{"key":"e_1_2_10_11_1","volume-title":"Long\u2010term real\u2010world experience of CPX\u2010351 in combined French\u2010Italian cohorts identified high rate of negative measurable residual disease (MRD) and prolonged overall survival","author":"Thomas Cluzeau FG","year":"2023"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188888"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-014-0315-4"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47293-4"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T07:14:07Z","timestamp":1747725247000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,25]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/bjh.19967"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19967","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,25]]},"assertion":[{"value":"2024-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}